Pluri Inc. (PLUR): Customer Relationships and CDMO Monetization — What Investors Should Know

Pluri operates as a dual business: a therapeutic developer and a commercial contract manufacturer. The company monetizes through licensing its cell-based technologies, royalties from sector partners, and fee-for-service revenues from its PluriCDMO™ contract development and manufacturing business, while maintaining selective joint ventures in alternative industries such as cultivated food. With a market capitalization near $36 million and trailing twelve‑month revenue of roughly $1.34 million against a negative EBITDA, the enterprise is an early-stage commercial operator where partnerships and manufacturing contracts are the primary levers for near-term cash generation. For more on Pluri’s commercial footprint, visit https://nullexposure.com/.

How Pluri’s commercial engine actually runs

Pluri commercializes its proprietary placental and 3D cell‑based technologies in two clear channels. First, licensing and JV arrangements translate IP into non‑clinical revenue streams and potential royalties (the company has already executed such deals in AgTech and food). Second, PluriCDMO™ sells GMP manufacturing and process‑transfer services to biotech clients, taking on process implementation, engineering runs and clinical‑grade batch production.

Company-level operating signals reinforce that duality:

• Contracting posture is mixed. Pluri manages both multi‑year, higher‑value engagements (for example, a disclosed three‑year $4.2 million contract with NIAID) and a number of short‑duration performance obligations treated under a practical expedient because they originally span less than one year. This creates a revenue profile with pockets of predictability and a broader base of transactional CDMO work.
• Pluri acts primarily as a service provider. Public disclosures state that the company derives most revenue from CDMO services and point‑of‑concept collaborations with large agriculture partners, indicating service revenue is the near-term cash driver.
• Segment focus is manufacturing and services. The formal launch of PluriCDMO™ in January 2024 signals the company’s strategic pivot toward industrialized cell expansion and GMP manufacturing as a repeatable commercial offering.
• Maturity is early. PluriCDMO™ is newly established and currently generating initial revenues, implying commercial scale and margin stability are still developing.

Client relationships: who uses Pluri’s platform

Ever After Foods — cultivation licensing outside human therapeutics

Pluri granted Ever After Foods an exclusive global, royalty‑bearing license to apply Pluri’s IP and expertise to cultivated meat, positioning Pluri as an IP licensor in the alternative‑protein market. This deal expands Pluri’s reach beyond therapeutics into food production (AGFunderNews, March 10, 2026: https://agfundernews.com/ever-after-foods-addresses-critical-scaling-challenge-in-cultivated-meat).

Remedy Cell Ltd. — scale‑up and clinical‑grade manufacturing customer

Pluri expanded a 2024 manufacturing agreement with Remedy Cell, executing process transfer, GMP training, engineering runs and manufacture of clinical‑grade batches of Remedy Cell’s lead candidate—an example of PluriCDMO™ delivering end‑to‑end clinical manufacturing services (GlobeNewswire / ManilaTimes, December 22, 2025 and March 2026 releases: https://www.manilatimes.net/2025/12/22/tmt-newswire/globenewswire/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved/2247958 and https://www.manilatimes.net/2026/01/22/tmt-newswire/globenewswire/pluri-successfully-completes-first-phase-of-resbiomed-program-for-placenta-derived-collagen-rich-biomaterials/2263691).

Resbiomed Technologies OOD — placenta-derived biomaterials development through PluriCDMO™

Pluri executed a program with Resbiomed to apply its placenta‑derived processing and bioprocessing capabilities to standardize and scale production of collagen‑rich biomaterials, with the first phase of the program reported complete under PluriCDMO™ (Proactive Investors and Intellectia summaries, March 2026: https://www.proactiveinvestors.com.au/companies/news/1087048/pluri-showcases-cell-expansion-platform-as-resbiomed-program-advances.html and https://intellectia.ai/en/stock/PLUR/news).

Tnuva Group / Tnuva — strategic joint venture in cultured food

Pluri’s first collaboration was a joint venture announced in January 2022 with Israeli food giant Tnuva to develop a platform for cultured meat, with optional expansion into cultured fish and dairy, illustrating Pluri’s early diversification into AgTech/food licensing and JV structures (The Jerusalem Post, Finance Yahoo and GlobeNewswire press materials, FY2022: https://www.jpost.com/business-and-innovation/tech-and-start-ups/article-716164 and https://finance.yahoo.com/news/pluristem-therapeutics-inc-changes-name-050000542.html).

What the relationship mix implies about risk and opportunity

• Revenue concentration and customer mix. Pluri’s revenue mix tilts toward CDMO contracts and a handful of strategic collaborations and licenses; this creates concentration risk but also higher revenue visibility where multi‑year and clinical manufacturing contracts exist.
• Customer criticality is high for executed GMP work. Process transfer, GMP training, engineering runs and clinical‑grade manufacturing are mission‑critical activities for partner programs, which enhances stickiness and contract renewal potential when Pluri demonstrates robust execution.
• Contract maturity is uneven. The presence of both a disclosed multi‑year NIH/NIAID contract and shorter performance obligations implies a portfolio approach—some predictable, higher‑value contracts coexist with transactional work treated as short‑term revenue.
• Business model tailwinds and constraints. The launch of PluriCDMO™ provides a scalable commercial avenue to monetize platform expertise beyond internal therapeutics, but commercial scale, pricing power and margin expansion are contingent on executing a pipeline of CDMO engagements and expanding the customer base.

Visit https://nullexposure.com/ for more primary‑source translations of Pluri’s partnership announcements and contract disclosures.

Bottom line: what investors should watch

• Execution on PluriCDMO™ is the single most important commercial signal—repeatable GMP manufacturing wins and successful process transfers (e.g., Remedy Cell, Resbiomed) will validate unit economics and increase utilization.
• Licensing and JV outcomes are optional upside. Deals like Ever After and Tnuva expand addressable markets and can produce royalties or equity upside if scaled.
• Contract profile matters. Monitor the pipeline of multi‑year vs. short‑term contracts, as the mix determines revenue predictability and cash flow runway; the disclosed three‑year NIH/NIAID engagement is material context for public revenue stability.
• Watch margins and capital intensity. Clinical‑grade manufacturing scales revenue but requires capital and operational maturity to convert top‑line into sustainable EBITDA improvement.

Key takeaway: Pluri is a small‑cap biotech that has converted proprietary cell technologies into a nascent CDMO and licensing engine; near‑term value accrues to investors if PluriCDMO™ converts pilot clients into recurring, higher‑value GMP contracts while maintaining disciplined execution on process transfer and clinical manufacturing.